glp 1 日本 GLP-1受容体作動薬 なぜ"やせ薬"GLP-1は日本で批判されるのか メディアの偏向報道､専門医の縄張り意識…医師が明かす根本的な問題 | ライフ |

Their use is rising rapidly, and with good reason: These medications have been shown to reduce blood sugar, improve fatty liver, GERD, sleep apnea, osteoarthritis, blood pressure, triglycerides, major adverse cardiovascular events, and even show potential benefits for conditions like alcohol use disorder (Mozaffarian et al., 2025

January 10, 2023

Since muscle is metabolically active, losing it slows metabolism and increases the risk of weight regain when stopping GLP-1 treatment

Heart failure with preserved ejection fraction (HFpEF) (e.g, STEP-HFpEF and SUMMIT), 4

For consumers, the take-home message is balanced: there is enough reassurance to support use in appropriate patients, but not enough reason to dismiss the warning entirely

Methods Using a subset of Truveta Data, we found a population of adolescent patients (aged 12-17 years old) who had a recorded body mass index (BMI) on the same day as an outpatient visit between January 1, 2021 and March 31, 2025